Lynn E. DeLisi, MD, is currently an Attending Psychiatrist in the VA Boston Healthcare System and Professor of Psychiatry at Harvard Medical School. In addition, she is Editor-in-Chief of the Elsevier journal, Psychiatry Research. She was secretary, as well as co-founder, of two professional organizations: The Schizophrenia International Research Society (SIRS), of which she is President, and the International Society of Psychiatric Genetics (ISPG). She is also an active fellow of the American College of Neuropsychopharmacology.
Her undergraduate degree is in zoology and is from the University of Wisconsin, Madison, Wisconsin. She obtained her M.D. degree from the Medical College of Pennsylvania and went on from there to do 3 years of general practice work with the migrant chile farmers of Northern New Mexico. She completed a residency in psychiatry at Saint Elizabeth’s Hospital, Washington DC, and then went on to complete a post-doctoral fellowship and then remained as a full-time staff research psychiatrist in the NIMH intramural research program, at both St. Elizabeth’s Hospital and in Bethesda, Maryland. In 1987, she left NIMH to assume a professorship at the State University of New York at Stony Brook where she set up several research programs, including one on the longitudinal biological outcome of schizophrenia, emphasizing both brain imaging and genetic studies. During this time, she was the first to conduct a longitudinal controlled MRI study that showed progressive brain change in schizophrenia and was a pioneer in developing an international collaboration for ascertainment of families with multiple members having schizophrenia to be used in molecular genetic studies.
From 2001 through 2008, she was professor of psychiatry at New York University Langone School of Medicine and Associate Director of the Center for Advanced Brain Imaging at the Nathan Kline Institute for Psychiatric Research where she contributed several studies on anomalies of language processing in people at high risk for schizophrenia. She moved to her current position in the Boston area in January 2009 where she continues to focus her research on biological markers for high risk for schizophrenia, studies of PTSD and drug addictions, including marijuana and opiates, and studies bringing genetics into the clinics.
In addition, she has been working with her local community on committees focused on regulation of the use of marijuana and is the Vice-Chairperson of her town's Planning Board. She teaches residents, medical students and the public about multiple aspects of mental illnesses.
Til Wykes is Professor of Clinical Psychology and Rehabilitation and Vice Dean for Psychology and Systems Sciences at the Institute of Psychiatry, Psychology, and Neuroscience at King’s College London. Her active research stretches across the impact pathway which includes a basic understanding of the causes and effects of psychosis, the development, and evaluation of novel psychological treatments and testing implementation so they can be rolled out into services. She also has research in digital health and active and passive monitoring. She actively collaborates with consumers in the Service User Research Enterprise (SURE) (founder and co-director) and leads the Patient and Carer Participation theme of the NIHR Biomedical Research Centre in Mental Health.
She has been the chair of the SIRS Ethics Committee as well as Secretary and Treasurer of the Society. She is the executive editor of the Journal of Mental Health and serves on the editorial boards of npj Schizophrenia, Schizophrenia Research, and Schizophrenia Bulletin. She is an elected fellow of the Academy of Medical Sciences, the Academy of Social Sciences and the British Psychological Society. In 2016 her work was recognized through the award of a Damehood by the Queen and in 2017 she achieved a Guinness World Record for the largest mental health lesson.
Prof Paola Dazzan is Professor of Neurobiology of Psychosis, in the Department of Psychosis Studies at the Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, and Honorary Consultant Perinatal Psychiatrist, South London and Maudsley NHS Foundation Trust.
She completed her Medical Degree at the University of Cagliari, Italy and obtained a Fellowship in psychiatry that allowed her to pursue her research interests in the UK. She became a Member of the Royal College of Psychiatrists (MRCPsych) in 1998. In 2002, she completed a Master (MSc) in Psychiatry at the Institute of Psychiatry, King’s College London. She trained as a psychiatrist at the Maudsley Hospital and completed her Ph.D. at the Institute of Psychiatry, King’s College London, in 2006. In 2013 she was nominated Fellow of the Royal College of Psychiatrists (FRCPsych).
Prof Dazzan’s main area of research interest is neuroimaging and its application to the study of early psychosis and postpartum psychoses. She is internationally known for her work on the relationship between magnetic resonance imaging (MRI) data and other biological measures such as neurodevelopmental indices, stress, and reproductive hormones. She has studied these phenomena in the early stages of psychosis and her interest has developed to include the progression of brain structural changes over the course of psychoses and the biological substrate of postpartum psychoses. She has a strong interest in understanding how antipsychotic drugs affect brain structure and function, and in exploring how to use imaging to predict response to treatment and clinical outcome. Her work has been extensively published in high impact papers, with more than 200 publications and an h-index of 61 (Google Scholar), and has been recognised by several prestigious International Awards, including the 2014 Academic Researcher of the Year Award from the Royal College of Psychiatrists, and Honorary Membership of the American Psychiatric Association in recognition of her contribution to psychiatry. In 2017 she received the Guy’s, King’s and St Thomas’s Award for “Outstanding Contribution to Student Experience”, for her work as Lead of Psychiatry teaching in the Medical School.
She has a strong interest in addressing gender inequality and promoting diversity in the academic environment, and until recently was the Co-Chair of the Diversity and Inclusion Team of the Institute of Psychiatry, Psychology and Neuroscience, the group that produced the application for the Athena Silver Award obtained by the Faculty. She is a member of the Executive Committees of the Academic and the Perinatal Faculties of the Royal College of Psychiatrists and of the Board of Directors of the Schizophrenia International Research Society. In November 2017 she was appointed Vice Dean International for the Institute of Psychiatry, Psychology, and Neuroscience.
Robert W. Buchanan, M.D. is a Professor of Psychiatry in the Department of Psychiatry, University of Maryland School of Medicine; Director of the Maryland Psychiatric Research Center (MPRC); and Director of the Maryland Early Intervention Program (EIP). Major research interests include schizophrenia phenomenology; the neuroanatomical and behavioral investigation of the pathophysiology of schizophrenia; and the development of novel pharmacological approaches for negative symptoms, cognitive impairments, treatment-resistant positive symptoms, and the metabolic disturbances and other side effects associated with antipsychotic treatment.
Dr. Buchanan has conducted a series of proof of concept and clinical trials examining antipsychotic-reduction strategies in the acute and maintenance treatment of schizophrenia; the use of adjunctive pharmacological agents for the treatment of negative symptoms and cognitive impairments; and the comparative efficacy of clozapine and olanzapine for positive and negative symptoms and cognitive impairment in partially responsive outpatients with schizophrenia. He played a major role in the development and update of the Schizophrenia Patient Outcomes Research Team (PORT) psychopharmacological treatment recommendations. These are a set of evidence-based recommendations that have influenced the development of various sets of treatment algorithms and guidelines for schizophrenia. He is currently funded to evaluate the neural basis of social cognitive impairments and to develop novel therapeutic approaches for the treatment of positive and negative symptoms and cognitive impairments in people with schizophrenia.